Pharmacological treatment of ambulatory schizophrenic patients in Belgium

Clinical Practice and Epidemiology in Mental Health

Volumn 2, Issue , 2006, Pages

  Hanssens, Linda ^a   De Hert, Marc ^b   Wampers, Martien ^b   Reginster, J Y ^a   Peuskens, Jozef ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AMBULATORY CARE; ARTICLE; AWARENESS; BELGIUM; CONSULTATION; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE REGIMEN; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GEOGRAPHY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SPECIALIST; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; SAMPLING; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 33745500637     PISSN: 17450179     EISSN: None     Source Type: Journal    
DOI: 10.1186/1745-0179-2-11     Document Type: Article

References (25)

1. Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988, 45:79-91.
2. Kulkarni J, Power P: Initial treatment of first-episode psychosis. In The recognition and management of early psychosis Edited by: McGorry P, Jackson H. Cambridge: University Press; 1999:184-205.
3. NICE (National Institute for Clinical Excellence): Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: NICE; 2002.
4. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-564.
5. De Hert M, Peuskens J: Schizofrene psychose. Welzijnsgids - Gezondheidszorg, Geestelijke Gezondheid 2002:161-186.
6. Kane JM, Leucht S, Carpenter D, Docherty JP: Expert consensus guideline series. Optimising pharmacologic treatment of psychotic disorders. Introduction: methods, commentary and summary. J Clin Psychiatry 2003:5-19.
7. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, Bilder R: Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996:5-9.
8. Peuskens J, De Hert M: Good medical practice antipsychotics Copenhague: Lundbeck; 1999.
9. Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ: Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry 1999, 60:47-751.
10. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of neuroleptic threshold en higher haloperidol dose. Arch Gen Psychiatry 1991, 48:739-745.
11. Robben N, De Hert M, Peuskens J: Gebrek aan ziekte-inzicht bij schizofrene patiënten. Tijdschrift voor Psychiatrie 2002, 44:313-322.
12. Harrington M, Lelliott P, Paton C, Konsolaki M, Sensky T, Okocha C: Variations between services in polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bulletin 2002, 26:418-420.
13. Janssen F, Peuskens J, D'haenens M, De Hert M, Hulselmans J, Meire I: Geheugenstoornissen bij schizofrene patiënten. Neuron 2001:2-10.
14. Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C: The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for inpatients. Psychiatric Bulletin 2002, 26:411-414.
15. Jones SH, Thornicroft G, Coffey M, Dunn G: A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning GAF. Br J Psychiatry 1995, 166:654-659.
16. Guy W: E.C.D.E.U. Assessment manual for psychopharmacology Rockville MD: Department of Health, Education and Welfare; 1976.
17. Blin P, Olie JP, Sechter D, Petitjean F, Cialdella P, Gerard A, Hanssens L, Westerloppe J: Utilisation des neuroleptiques chez les patients ambulatoires souffrant de schizophrónie. Rev Epidemiol Sonté Publique 2005, 53:601-613.
18. De Hert M, Van Eyck D, Peuskens H, Thys E, Wampers M, Scheen A, Peuskens J: Oral Glucose Tolerance Test in treated patients with schizophrenia: Data to support an adaptation of the proposed guidelines for monitoring patients on second generation antipsychotics. Eur Psychiatry 2005. available online
19. Buckley PF, Miller DD, Singer B: Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005, 79:281-288.
20. Newcomer JW, Nasrallah HA, Loebel AD: The atypical antipsychotic therapy and metabolic issues national survey. J Clin Psychopharmacol 2004, 24(Suppl):1-6.
21. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
22. Scheen AJ, De Hert M: Drug-induced diabetes mellitus: the example of atypical antipsychotics. Revue Med Liege 2005, 60(5-6):455-60.
23. American Diabetes Association: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004, 27:596-601.
24. De Hert M, van Winkel R. Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006, 83(1):87-93.
25. De Hert M, Thys E, Boydens J, Gillis P, Kesteloot K, Verhaegen L, Peuskens J: Health expenditure on schizophrenic patients in Belgium. Schizophr Bull 1988, 24(4):519-527.